is a minimally invasive treatment for PAD in which a catheter-based device is used to remove plaque from a blood vessel.
The new, smaller HawkOne 6F device further adds to the versatility of this directional atherectomy
system and enables us to treat a larger set of patients with more complex lesions, including patients with challenging calcified lesions.
According to the company, Pantheris is the first and only image-guided atherectomy
device to receive clearance for diagnostic imaging as well as for the simultaneous treatment of PAD.
Data from this study will be key to secure approval for the use of the coronary micro crown OAS in the world's two largest atherectomy
markets," said David L.
Goldstein about the cutting-edge techniques and new technologies used to perform atherectomy
of the lower extremities.
I've always been an advocate of using atherectomy
as a minimally invasive way to treat patients with PAD, said Dr.
will present "Pivotal Trial to Evaluate the Safety and Efficacy of Diamondback 360x Orbital Atherectomy
System in Treating De Novo, Severely Calcified Coronary Lesions (ORBIT II).
is a minimally invasive alternative to surgical bypass, until recently the preferred treatment for lower-extremity ischemia, he continued.
Kallok, PhD, CSI's CEO said, "OASIS is the first prospective multi center clinical trial for an atherectomy
device treating Peripheral Arterial Disease (PAD).
Schulte, Spectranetics' president and chief executive officer, said, "We are encouraged by growth in both our coronary atherectomy
and lead removal product lines.
They used atherectomy
along with angioplasty and stents in 6 percent of patients and atherectomy
with angioplasty but no stents in another 3 percent.
In 1990, Reeves had an atherectomy
, the removal of a blockage.
M2 PHARMA-October 6, 2016-Ra Medical Systems' Debra Atherectomy
, Pharos Laser Phototherapy Systems Approved in Europe
The VIVA sponsored study is assessing outcomes for patients with significantly calcified and symptomatic femoropopliteal peripheral artery disease (PAD), following adjunctive use of directional atherectomy
and drug-coated balloon (DCB).
25 million to resolve allegations under the False Claims Act that Fox Hollow caused certain hospitals to submit false claims to Medicare for unnecessary inpatient admissions related to minimally invasive atherectomy
procedures, according to the U.